Ahead Therapeutics has reached an agreement with Dr. Rozen Le Panse from the Institute of Myology from Paris to stride forward with the preclinical development of AT_1616.
The agreement will allow Ahead Therapeutics to validate the platform potential of the PS-Liposomes using a Myasthenia Gravis in vivo model settled up by the group of Dr. Le Panse. All the experiments will be performed at the Institute of Myology by researchers from Dr. Le Panse’s group.
